FDA Changes Fluoroquinolone Label But Denies Citizen Petition on Mitochondrial Toxicity

On Thursday May 12, 2016 the FDA contacted those who have been pursuing label changes for the Fluoroquinolones and issued a public statement that the FDA is requiring label changes for antibacterial drugs called fluoroquinolones

Dr. Bennett Publishes Paper on Fluoroquinolone Neuropsychiatric & Mitochondrial Toxicity

Dr. Charles Bennett has been able to successfully publish a paper titled "Fluoroquinolone-Related Neuropsychiatric and Mitochondrial Toxicity: a collaborative investigation by scientists and members of a social network."

The Voices Heard Round The World – The November 5th FDA Meeting

On Nov. 5th, the true stars of our community took to the podium at the FDA to tell their personal stories. I, along with countless others, were humbled and honored. This meeting represented a huge step in the progress we are making to gain complete recognition of the travesty that the fluoroquinolone class of pharmaceuticals has wrought upon society, to achieve justice for those that have been damaged by these drugs, and to prevent future unnecessary pain and suffering not only for this generation, but for generations to come.

FDA To Hold Upcoming Meeting on Fluoroquinolones

We believe that the attention given the Fluoroquinolones through the combined media stories, past rallies, citizen petitions, in addition to community members meeting directly with FDA officials, provided some of the impetus, in part, for the scrutiny of the Fluoroquinolones being prescribed for these common health conditions.

Fluoroquinolone Community Goes to the FDA: Pediatrics and Rhabdomyolysis

On August 24th, 2015, members from the FQ community met with staff from the FDA in a third meeting to address the various FDA failures to adequately warn the general public about the true dangers FQ's pose to the general public, especially our children.

Go to Top